We are international

ASH 2011: Dr. Richardson - Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results
Paul G. Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA

To view the video full screen, click on the small button next to the volume control in the lower right hand corner.

 related articles